Trial
NCT03568071
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Lakefront Biotherapeutics NV
Collaborators
—
Condition
Atopic Dermatitis
Intervention
MOR 106
Why stopped
MOR106 clinical development in atopic dermatitis was stopped for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-18